Giampaolo Tortora

Summary

Affiliation: Federico II University
Country: Italy

Publications

  1. ncbi request reprint Key cancer cell signal transduction pathways as therapeutic targets
    Roberto Bianco
    Dipartimento di Endocrinologia e Oncologia Molecolare e Clinica, Universita di Napoli Federico II, Via S Pansini 5, 80131 Napoli, Italy
    Eur J Cancer 42:290-4. 2006
  2. ncbi request reprint [New frontiers in cancer treatment]
    Giampaolo Tortora
    Cattedra di Oncologia Medica e Laboratori di Terapia Molecolare, Dipartimento di Endocrinologia e Oncologia Molecolare e Clinica, Universita Federico II, Napoli
    Recenti Prog Med 97:781-6. 2006
  3. ncbi request reprint Angiogenesis: a target for cancer therapy
    Giampaolo Tortora
    Division of Medical Oncology, Department of Molecular and Clinical Endocrinology and Oncology, Universita di Napoli Federico II, Via S Pansini 5, 80131 Naples, Italy
    Curr Pharm Des 10:11-26. 2004
  4. ncbi request reprint Antisense targeting protein kinase A type I as a drug for integrated strategies of cancer therapy
    Giampaolo Tortora
    Division of Medical Oncology, Department of Molecular and Clinical Endocrinology and Oncology, Universita di Napoli Federico II, 80131 Napoli, Italy
    Ann N Y Acad Sci 1002:236-43. 2003
  5. ncbi request reprint Rational bases for the development of EGFR inhibitors for cancer treatment
    Roberto Bianco
    Dipartimento di Endocrinologia e Oncologia Molecolare e Clinica, Universita di Napoli Federico II, Via S Pansini 5, 80131 Naples, Italy
    Int J Biochem Cell Biol 39:1416-31. 2007
  6. ncbi request reprint A meta-analysis on the interaction between HER-2 expression and response to endocrine treatment in advanced breast cancer
    Michele De Laurentiis
    Dipartimento di Endocrinologia ed Oncologia Molecolare e Clinica, Universita Federico II, Napoli, Italy
    Clin Cancer Res 11:4741-8. 2005
  7. ncbi request reprint Combination of a selective cyclooxygenase-2 inhibitor with epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 and protein kinase A antisense causes cooperative antitumor and antiangiogenic effect
    Giampaolo Tortora
    Dipartimento di Endocrinologia e Oncologia Molecolare e Clinica, Universita di Napoli Federico II, 80131 Napoli, Italy
    Clin Cancer Res 9:1566-72. 2003
  8. ncbi request reprint Rational combination of targeted therapies as a strategy to overcome the mechanisms of resistance to inhibitors of EGFR signaling
    Roberto Bianco
    Dipartimento Medico Chirurgico di Internistica Clinica e Sperimentale, Seconda Universita di Napoli, Napoli, Italy
    Curr Pharm Des 13:3358-67. 2007
  9. ncbi request reprint In vitro expansion of human breast cancer epithelial and mesenchymal stromal cells: optimization of a coculture model for personalized therapy approaches
    Bianca Maria Veneziani
    Dipartimento di Biologia e Patologia Cellulare e Molecolare L Califano, Universita di Napoli Federico II, Via S Pansini 5, 80131 Naples, Italy
    Mol Cancer Ther 6:3091-100. 2007
  10. ncbi request reprint Combined targeted inhibition of bcl-2, bcl-XL, epidermal growth factor receptor, and protein kinase A type I causes potent antitumor, apoptotic, and antiangiogenic activity
    Giampaolo Tortora
    Dipartimento di Endocrinologia e Oncologia Molecolare e Clinica, Universita di Napoli Federico II, 80131 Napoli, Italy
    Clin Cancer Res 9:866-71. 2003

Collaborators

Detail Information

Publications52

  1. ncbi request reprint Key cancer cell signal transduction pathways as therapeutic targets
    Roberto Bianco
    Dipartimento di Endocrinologia e Oncologia Molecolare e Clinica, Universita di Napoli Federico II, Via S Pansini 5, 80131 Napoli, Italy
    Eur J Cancer 42:290-4. 2006
    ....
  2. ncbi request reprint [New frontiers in cancer treatment]
    Giampaolo Tortora
    Cattedra di Oncologia Medica e Laboratori di Terapia Molecolare, Dipartimento di Endocrinologia e Oncologia Molecolare e Clinica, Universita Federico II, Napoli
    Recenti Prog Med 97:781-6. 2006
    ..The future goal of cancer therapy will be the tailoring of treatments based on the specific molecular features of the tumor of each patient, with the aim to obtain the maximum therapeutic efficacy with the lowest toxicity...
  3. ncbi request reprint Angiogenesis: a target for cancer therapy
    Giampaolo Tortora
    Division of Medical Oncology, Department of Molecular and Clinical Endocrinology and Oncology, Universita di Napoli Federico II, Via S Pansini 5, 80131 Naples, Italy
    Curr Pharm Des 10:11-26. 2004
    ..In this review will be discussed the signal transduction mechanisms of angiogenic molecules, the development of specific inhibitors and their translation into clinical studies and, finally, the new perspectives in antiangiogenic therapy...
  4. ncbi request reprint Antisense targeting protein kinase A type I as a drug for integrated strategies of cancer therapy
    Giampaolo Tortora
    Division of Medical Oncology, Department of Molecular and Clinical Endocrinology and Oncology, Universita di Napoli Federico II, 80131 Napoli, Italy
    Ann N Y Acad Sci 1002:236-43. 2003
    ..These studies support the development of AS-PKAI as a novel anticancer agent and suggest its potentially relevant role when integrated with conventional treatments and/or other signaling inhibitors in novel therapeutic strategies...
  5. ncbi request reprint Rational bases for the development of EGFR inhibitors for cancer treatment
    Roberto Bianco
    Dipartimento di Endocrinologia e Oncologia Molecolare e Clinica, Universita di Napoli Federico II, Via S Pansini 5, 80131 Naples, Italy
    Int J Biochem Cell Biol 39:1416-31. 2007
    ..This article reviews the EGFR role in carcinogenesis and tumor progression as rational bases for the development of specific therapeutic inhibitors...
  6. ncbi request reprint A meta-analysis on the interaction between HER-2 expression and response to endocrine treatment in advanced breast cancer
    Michele De Laurentiis
    Dipartimento di Endocrinologia ed Oncologia Molecolare e Clinica, Universita Federico II, Napoli, Italy
    Clin Cancer Res 11:4741-8. 2005
    ..Clinical data, however, have been conflicting. We have conducted a meta-analysis on the interaction between the response to endocrine treatment and the overexpression of HER-2 in metastatic breast cancer...
  7. ncbi request reprint Combination of a selective cyclooxygenase-2 inhibitor with epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 and protein kinase A antisense causes cooperative antitumor and antiangiogenic effect
    Giampaolo Tortora
    Dipartimento di Endocrinologia e Oncologia Molecolare e Clinica, Universita di Napoli Federico II, 80131 Napoli, Italy
    Clin Cancer Res 9:1566-72. 2003
    ..Therefore, we investigated whether any cooperative antitumor effect can be obtained by the combined blockade of COX-2, EGFR, and PKAI...
  8. ncbi request reprint Rational combination of targeted therapies as a strategy to overcome the mechanisms of resistance to inhibitors of EGFR signaling
    Roberto Bianco
    Dipartimento Medico Chirurgico di Internistica Clinica e Sperimentale, Seconda Universita di Napoli, Napoli, Italy
    Curr Pharm Des 13:3358-67. 2007
    ..This review focuses on the role of complementary signalling pathways in the development of resistance to EGFR targeting agents and the rationale to combine novel inhibitors as anticancer therapy...
  9. ncbi request reprint In vitro expansion of human breast cancer epithelial and mesenchymal stromal cells: optimization of a coculture model for personalized therapy approaches
    Bianca Maria Veneziani
    Dipartimento di Biologia e Patologia Cellulare e Molecolare L Califano, Universita di Napoli Federico II, Via S Pansini 5, 80131 Naples, Italy
    Mol Cancer Ther 6:3091-100. 2007
    ....
  10. ncbi request reprint Combined targeted inhibition of bcl-2, bcl-XL, epidermal growth factor receptor, and protein kinase A type I causes potent antitumor, apoptotic, and antiangiogenic activity
    Giampaolo Tortora
    Dipartimento di Endocrinologia e Oncologia Molecolare e Clinica, Universita di Napoli Federico II, 80131 Napoli, Italy
    Clin Cancer Res 9:866-71. 2003
    ....
  11. ncbi request reprint Protein kinase A as target for novel integrated strategies of cancer therapy
    Giampaolo Tortora
    Cattedra di Oncologia Medica, Dipartimento di Endocrinologia e Oncologia Molecolare e Clinica, Universita di Napoli Federico II, 80131 Napoli, Italy
    Ann N Y Acad Sci 968:139-47. 2002
    ..Finally, we have shown that AS-PKA-I also has antitumor and antiangiogenic effects following oral administration and that they can be greatly enhanced in combination with oral ZD1839 and oral taxanes...
  12. doi request reprint Combined targeting of EGFR-dependent and VEGF-dependent pathways: rationale, preclinical studies and clinical applications
    Giampaolo Tortora
    Clinical Unit and Laboratories of Molecular Therapy at the University of Naples Federico II, Naples, Italy
    Nat Clin Pract Oncol 5:521-30. 2008
    ..This Review discusses the experimental rationale for, preclinical studies of and clinical trials on combined blockade of ERBB and VEGF signaling...
  13. ncbi request reprint Synergistic antitumor activity of ZD6474, an inhibitor of vascular endothelial growth factor receptor and epidermal growth factor receptor signaling, with gemcitabine and ionizing radiation against pancreatic cancer
    Cataldo Bianco
    Division of Radiotherapy, Department of Oncology, Transplants and Advanced Technologies in Medicine, University of Pisa, Pisa, Italy
    Clin Cancer Res 12:7099-107. 2006
    ....
  14. ncbi request reprint Anti-tumor activity of the combination of cetuximab, an anti-EGFR blocking monoclonal antibody and ZD6474, an inhibitor of VEGFR and EGFR tyrosine kinases
    Maria Pia Morelli
    Dipartimento Medico Chirurgico di Internistica Clinica e Sperimentale F Magrassi e A Lanzara, Seconda Universita degli Studi di Napoli, Napoli, Italy
    J Cell Physiol 208:344-53. 2006
    ....
  15. ncbi request reprint Novel toll-like receptor 9 agonist induces epidermal growth factor receptor (EGFR) inhibition and synergistic antitumor activity with EGFR inhibitors
    Vincenzo Damiano
    Dipartimento di Endocrinologia e Oncologia Molecolare e Clinica, Istituto di Anatomia Patologica, and Dipartimento di Biologia e Patologia Cellulare e Molecolare, Universita di Napoli Federico II, Via S Pansini 5, 80131 Naples, Italy
    Clin Cancer Res 12:577-83. 2006
    ..We hypothesized that modified TLR9 agonists could impair epidermal growth factor receptor (EGFR) signaling and, by this means, greatly enhance EGFR inhibitors effect, acting on both the receptor targeting and the immunologic arm...
  16. pmc Overcoming resistance to molecularly targeted anticancer therapies: Rational drug combinations based on EGFR and MAPK inhibition for solid tumours and haematologic malignancies
    Giampaolo Tortora
    Dipartimento di Endocrinologia e Oncologia Molecolare e Clinica, Universita di Napoli Federico II, Naples, Italy
    Drug Resist Updat 10:81-100. 2007
    ....
  17. ncbi request reprint Zoledronic acid cooperates with a cyclooxygenase-2 inhibitor and gefitinib in inhibiting breast and prostate cancer
    Davide Melisi
    Cattedra di Oncologia Medica, Dipartimento di Endocrinologia e Oncologia Molecolare e Clinica, Universita di Napoli Federico II, Naples, Italy
    Endocr Relat Cancer 12:1051-8. 2005
    ....
  18. doi request reprint Gefitinib induction of in vivo detectable signals by Bcl-2/Bcl-xL modulation of inositol trisphosphate receptor type 3
    Antonella Zannetti
    Institute of Biostructures and Bioimages, National Research Council
    Clin Cancer Res 14:5209-19. 2008
    ..To test whether epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKI) induce detectable signals in tumor cells and whether such signals may reveal alterations of the apoptotic program...
  19. ncbi request reprint Primary and acquired resistance to anti-EGFR targeted drugs in cancer therapy
    Floriana Morgillo
    Dipartimento Medico Chirurgico di Internistica Clinica e Sperimentale F Magrassi e A Lanzara, Seconda Universita degli Studi di Napoli, Via Pansini 5 80131 Napoli, Italy
    Differentiation 75:788-99. 2007
    ..This review will focus on the most relevant mechanisms contributing to the acquisition of sensitivity/resistance to EGFR inhibitors...
  20. doi request reprint Vascular endothelial growth factor receptor-1 contributes to resistance to anti-epidermal growth factor receptor drugs in human cancer cells
    Roberto Bianco
    Cattedra di Oncologia Medica, Dipartimento di Endocrinologia e Oncologia Molecolare e Clinica, Universita di Napoli Federico II, Via S Pansini 5, Naples, Italy
    Clin Cancer Res 14:5069-80. 2008
    ..Combined inhibition of EGFR and other signaling proteins has become a successful therapeutic approach, stimulating the search for further determinants of resistance as basis for novel therapeutic strategies...
  21. pmc LY2109761, a novel transforming growth factor beta receptor type I and type II dual inhibitor, as a therapeutic approach to suppressing pancreatic cancer metastasis
    Davide Melisi
    Department of Gastrointestinal Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Mol Cancer Ther 7:829-40. 2008
    ..Targeting TbetaRI/II kinase activity on pancreatic cancer cells or the cells of the liver microenvironment represents a novel therapeutic approach to prevent pancreatic cancer metastasis...
  22. ncbi request reprint The use of xenograft models for the selection of cancer treatments with the EGFR as an example
    Teresa Troiani
    Dipartimento Medico Chirurgico di Internistica Clinica e Sperimentale F Magrassi e A Lanzara, Seconda Universita degli Studi di Napoli, Naples, Italy
    Crit Rev Oncol Hematol 65:200-11. 2008
    ..Here we review the value and the limitations of xenograft models and their role in developing new anti-cancer treatments...
  23. doi request reprint Synergistic anti-proliferative and pro-apoptotic activity of combined therapy with bortezomib, a proteasome inhibitor, with anti-epidermal growth factor receptor (EGFR) drugs in human cancer cells
    Tina Cascone
    Division of Medical Oncology, Department of Clinical and Experimental Medicine and Surgery F Magrassi and A Lanzara, Second University of Naples, Naples, Italy
    J Cell Physiol 216:698-707. 2008
    ....
  24. doi request reprint EGFR antagonists in cancer treatment
    Fortunato Ciardiello
    Division of Medical Oncology, Department of Experimental and Clinical Medicine and Surgery F Magrassi and A Lanzara, Second University of Naples, Naples, Italy
    N Engl J Med 358:1160-74. 2008
  25. ncbi request reprint Phase II trial of cetuximab in combination with fluorouracil, leucovorin, and oxaliplatin in the first-line treatment of metastatic colorectal cancer
    Josep Tabernero
    Medical Oncology Department, Vall d Hebron University Hospital, P Vall d Hebron, 119 129, 08035 Barcelona, Spain
    J Clin Oncol 25:5225-32. 2007
    ....
  26. pmc TLR9 agonist acts by different mechanisms synergizing with bevacizumab in sensitive and cetuximab-resistant colon cancer xenografts
    Vincenzo Damiano
    Departments of Endocrinologia e Oncologia Molecolare e Clinica, Universita di Napoli Federico II, 80131 Napoli, Italy
    Proc Natl Acad Sci U S A 104:12468-73. 2007
    ....
  27. ncbi request reprint Combined targeting of endothelin A receptor and epidermal growth factor receptor in ovarian cancer shows enhanced antitumor activity
    Laura RosanĂ²
    Molecular Pathology Laboratory, Regina Elena Cancer Institute, Rome, Italy
    Cancer Res 67:6351-9. 2007
    ..The cross-signaling between the EGFR/ET(A)R pathways provides a rationale to combine EGFR inhibitors with ET(A)R antagonists, identifying new effective therapeutic opportunities for ovarian cancer...
  28. ncbi request reprint Intrinsic and acquired resistance to EGFR inhibitors in human cancer therapy
    Roberto Bianco
    Dipartimento di Endocrinologia Molecolare e Clinica, Universita degli Studi di Napoli Federico II, Naples, Italy
    Endocr Relat Cancer 12:S159-71. 2005
    ..However, the intrinsic molecular mechanisms of resistance to these drugs are still unclear. This review will focus on the preclinical findings on therapeutic resistance to EGFR targeting agents...
  29. ncbi request reprint Cooperative antitumor effect of multitargeted kinase inhibitor ZD6474 and ionizing radiation in glioblastoma
    Vincenzo Damiano
    Cattedra di Oncologia Medica, Dipartimento di Endocrinologia e Oncologia Molecolare e Clinica, Universita di Napoli Federico II, Italy
    Clin Cancer Res 11:5639-44. 2005
    ..We have investigated the antitumor and antiangiogenic effect of ZD6474, an inhibitor of both VEGFR and EGFR signaling as a single agent and in combination with ionizing radiation...
  30. ncbi request reprint Protein kinase A type I: a target for cancer therapy
    Giampaolo Tortora
    Clin Cancer Res 8:303-4. 2002
  31. ncbi request reprint Antitumor effects of ZD6474, a small molecule vascular endothelial growth factor receptor tyrosine kinase inhibitor, with additional activity against epidermal growth factor receptor tyrosine kinase
    Fortunato Ciardiello
    Cattedra di Oncologia Medica, Dipartimento di Endocrinologia e Oncologia Molecolare e Clinica, Universita degli Studi di Napoli Federico II, 5 80131 Naples, Italy
    Clin Cancer Res 9:1546-56. 2003
    ..ZD6474 is a p.o. bioavailable, VEGF flk-1/KDR receptor (VEGFR-2) tyrosine kinase inhibitor with antitumor activity in many human cancer xenografts and is currently in Phase I clinical development...
  32. ncbi request reprint ZD6474, an orally available inhibitor of KDR tyrosine kinase activity, efficiently blocks oncogenic RET kinases
    Francesca Carlomagno
    Istituto di Endocrinologia ed Oncologia Sperimentale del Consiglio Nazionale delle Ricerche, Dipartimento di Biologia e Patologia Cellulare e Molecolare Luigi Califano, University Federico II, Naples, Italy
    Cancer Res 62:7284-90. 2002
    ..Thus, targeting RET oncogenes with ZD6474 might offer a potential treatment strategy for carcinomas sustaining oncogenic activation of RET...
  33. ncbi request reprint Helicobacter pylori VacA toxin up-regulates vascular endothelial growth factor expression in MKN 28 gastric cells through an epidermal growth factor receptor-, cyclooxygenase-2-dependent mechanism
    Rosa Caputo
    Dipartimento di Internistica Clinica e Sperimentale Cattedra di Gastroenterologia, Seconda Universita di Napoli, Napoli, Italy
    Clin Cancer Res 9:2015-21. 2003
    ..We investigated: (a) whether H. pylori, and in particular H. pylori VacA toxin, affected VEGF expression in gastric epithelial cells in culture; and (b) the signal transduction pathway involved in any effect exerted by H. pylori...
  34. ncbi request reprint Enhancement of antitumor activity of ionizing radiation by combined treatment with the selective epidermal growth factor receptor-tyrosine kinase inhibitor ZD1839 (Iressa)
    Cataldo Bianco
    Cattedra di Oncologia Medica, Dipartimento di Endocrinologia e Oncologia Molecolare e Clinica, Universita degli Studi di Napoli Federico II, 80131 Naples, Italy
    Clin Cancer Res 8:3250-8. 2002
    ..The antitumor activity of this combination was also tested in nude mice bearing established GEO colon cancer xenografts...
  35. ncbi request reprint Anti-epidermal growth factor receptor drugs in cancer therapy
    Fortunato Ciardiello
    Cattedra di Oncologia Medica, Dipartimento di Endocrinologia e Oncologia Molecolare e Clinica, Universita di Napoli Federico II, Via S Pansini 5, 80131 Naples, Italy
    Expert Opin Investig Drugs 11:755-68. 2002
    ..Results from Phase I - II trials in advanced cancer demonstrate that these drugs have an acceptable tolerability and an interesting clinical activity in patients with a variety of tumour types...
  36. ncbi request reprint ZD1839 (Iressa): preclinical studies and pharmacology
    Fortunato Ciardiello
    Dipartimento di Endcorinologia e Oncologia Molecolare e Clinica, Facolta di Medicina e Chirurgia, Universita Federico II, Naples
    Tumori 88:S155-7. 2002
  37. ncbi request reprint ZD1839 (IRESSA), an EGFR-selective tyrosine kinase inhibitor, enhances taxane activity in bcl-2 overexpressing, multidrug-resistant MCF-7 ADR human breast cancer cells
    Fortunato Ciardiello
    Dipartimento di Endocrinologia e Oncologia Molecolare e Clinica, Universita di Napoli Federico II, Naples, Italy
    Int J Cancer 98:463-9. 2002
    ..These results demonstrate the ability of ZD1839 to overcome taxane resistance in a model of hormone-independent, multidrug-resistant, human breast cancer...
  38. ncbi request reprint Epidermal growth factor receptor tyrosine kinase inhibitors in late stage clinical trials
    Fortunato Ciardiello
    Cattedra di Oncologia Medica, Dipartimento Medico Chirurgico di Internistica Clinica e Sperimentale F Magrassi e A Lanzara, Seconda Universita degli Studi di Napoli, Via S Pansini 5, 80131 Napoli, Italy
    Expert Opin Emerg Drugs 8:501-14. 2003
    ..Furthermore, continuing clinical trials and a series of open clinical issues for the development of optimal strategies of using EGFR-targeting agents will be discussed...
  39. ncbi request reprint Antitumor activity of ZD6474, a vascular endothelial growth factor receptor tyrosine kinase inhibitor, in human cancer cells with acquired resistance to antiepidermal growth factor receptor therapy
    Fortunato Ciardiello
    Cattedra di Oncologia Medica, Dipartimento Medico Chirurgico di Internistica Clinica e Sperimentale F Magrassi e A Lanzara, Seconda Universita degli Studi di Napoli, Naples, Italy
    Clin Cancer Res 10:784-93. 2004
    ..ZD6474 is a small molecule VEGF flk-1/KDR (VEGFR-2) tyrosine kinase inhibitor that also demonstrates inhibitory activity against EGFR tyrosine kinase...
  40. ncbi request reprint Combined targeting of epidermal growth factor receptor and MDM2 by gefitinib and antisense MDM2 cooperatively inhibit hormone-independent prostate cancer
    Roberto Bianco
    Dipartimento di Endocrinologia e Oncologia Molecolare e Clinica, Universita di Napoli Federico II, Naples, Italy
    Clin Cancer Res 10:4858-64. 2004
    ..For this purpose, we have used the EGFR tyrosine kinase inhibitor gefitinib (ZD1839, Iressa) and a second generation hybrid oligonucleotide antisense MDM2 (AS-MDM2), respectively...
  41. ncbi request reprint The role of EGFR inhibitors in nonsmall cell lung cancer
    Fortunato Ciardiello
    Cattedra di Oncologia Medica, Dipartimento Medico Chirurgico di Internistica Clinica e Sperimentale F Magrassi e A Lanzara, Seconda Universita degli Studi di Napoli, Naples, Italy
    Curr Opin Oncol 16:130-5. 2004
    ..Several antiepidermal growth factor receptor agents are in clinical development. This review focuses on the available clinical data on epidermal growth factor receptor-targeting drugs in the treatment of nonsmall cell lung cancer...
  42. ncbi request reprint Chemosensitization by antisense oligonucleotides targeting MDM2
    Roberto Bianco
    Dipartimento di Endocrinologia e Oncologia Molecolare e Clinica, Universita di Napoli Federico II, Via S Pansini 5, 80131 Naples, Italy
    Curr Cancer Drug Targets 5:51-6. 2005
    ....
  43. ncbi request reprint Antitumor activity of ZD6126, a novel vascular-targeting agent, is enhanced when combined with ZD1839, an epidermal growth factor receptor tyrosine kinase inhibitor, and potentiates the effects of radiation in a human non-small cell lung cancer xenograft
    David Raben
    Department of Radiation Oncology, University of Colorado Health Sciences Center, Anschutz Cancer Pavilion, 1665 North Ursula Street, Suite 1032, Box F706, Aurora, CO 80010 0510, USA
    Mol Cancer Ther 3:977-83. 2004
    ....
  44. ncbi request reprint Antitumor activity of ZD6474, a vascular endothelial growth factor-2 and epidermal growth factor receptor small molecule tyrosine kinase inhibitor, in combination with SC-236, a cyclooxygenase-2 inhibitor
    Concetta Tuccillo
    Dipartimento Medico Chirurgico di Internistica Clinica e Sperimentale F Magrassi e A Lanzara, Seconda Universita degli Studi di Napoli, Via S Pansini 5, 80131 Naples, Italy
    Clin Cancer Res 11:1268-76. 2005
    ..We investigated the activity of ZD6474 in combination with SC-236, a selective COX-2 inhibitor, to determine the antitumor activity of the simultaneous blockade of EGFR, COX-2, and VEGF functions...
  45. ncbi request reprint Involvement of growth factor receptors of the epidermal growth factor receptor family in prostate cancer development and progression to androgen independence
    Giuseppe Di Lorenzo
    Department of Molecular and Clinical Endocrinology, Universita degli Studi di Napoli Federico II, Naples, Italy
    Clin Prostate Cancer 2:50-7. 2003
    ....
  46. ncbi request reprint Capecitabine plus weekly oxaliplatin in gastrointestinal tumors: a phase I study
    Chiara Carlomagno
    Dipartimento di Endocrinologia ed Oncologia Molecolare e Clinica, Universita di Napoli Federico II, Napoli, Italy
    Am J Clin Oncol 29:85-9. 2006
    ..To investigate the maximum tolerated dose (MTD) and the dose-limiting toxicity (DLT) of capecitabine plus oxaliplatin...
  47. ncbi request reprint Weekly docetaxel and vinorelbine (VIN-DOX) as first line treatment in patients with hormone refractory prostate cancer
    Giuseppe Di Lorenzo
    Cattedra di Oncologia Medica, Dipartimento di Endocrinologia ed Oncologia Molecolare e Clinica, Universita degli Studi Federico II, Naples, Italy
    Eur Urol 46:712-6. 2004
    ..The current study investigated the clinical benefit, the impact on biochemical and objective response and tolerability of weekly docetaxel with vinorelbine (VIN-DOX) in symptomatic patients with hormone refractory prostate cancer (HRPC)...
  48. ncbi request reprint Development of novel cancer chemopreventive agents in Europe--neglected Cinderella or rising phoenix? A critical commentary. ESF Workshop on Cancer Chemoprevention, DKFZ, Heidelberg, September 18-20, 2005
    Clarissa Gerhauser
    German Cancer Research Center, Toxicology and Cancer Risk Factors, Im Neuenheimer Feld 280, 69120 Heidelberg, Germany
    Eur J Cancer 42:1338-43. 2006
    ..Overall the workshop aimed at raising awareness among European clinical and laboratory researchers of the importance of the development of novel, efficacious and safe cancer preventive agents...
  49. ncbi request reprint [Rationales for the integration of molecular and conventional therapies]
    Giampaolo Tortora
    Cattedra di Oncologia Medica e Laboratorio di Oncologia Molecolare, Dipartimento di Endocrinologia e Oncologia Molecolare e Clinica, Universita di Napoli Federico II
    Tumori 88:A9-13. 2002
  50. ncbi request reprint Expression of epidermal growth factor receptor correlates with disease relapse and progression to androgen-independence in human prostate cancer
    Giuseppe Di Lorenzo
    Cattedra di Oncologia Medica, Dipartimento di Endocrinologia e Oncologia Molecolare e Clinica, Universita degli Studi di Napoli Federico II, 80131 Naples, Italy
    Clin Cancer Res 8:3438-44. 2002
    ..We investigated EGFR and c-erbB-2 expression in primary androgen-dependent and in advanced androgen-independent prostate cancer and their potential role as markers of disease progression...
  51. ncbi request reprint Epidermal growth factor receptor (EGFR) as a target in cancer therapy: understanding the role of receptor expression and other molecular determinants that could influence the response to anti-EGFR drugs
    F Ciardiello
    Cattedra di Oncologia Medica, Dipartimento Medico Chirurgico di Internistica Clinica e Sperimentale, Seconda Universita degli Studi di Napoli, Via S Pansini 5, 8013 Naples, Italy
    Eur J Cancer 39:1348-54. 2003
    ....
  52. ncbi request reprint Antisense strategies targeting protein kinase C: preclinical and clinical development
    Giampaolo Tortora
    Department of Molecular and Clinical Endocrinology and Oncology, Universita di Napoli Federico II, Naples, Italy
    Semin Oncol 30:26-31. 2003
    ..Studies in other tumor types will also investigate the benefit of combining LY900003 with conventional chemotherapy...